In spite of criticism, beta- beta-blockers remain preparations of selection in the treatment of the cardiovascular diseases


Дәйексөз келтіру

Толық мәтін

Аннотация

The problems associated with the use of beta-blockers (BAB) in essential arterial hypertension (AH) are discussed; in particular, we consider the possibility of using these drugs in patients with multiple metabolic risk factors, including metabolic syndrome and its components. It is emphasized that high cardioselektive BAB, such as bisoprolol, have no negative adverse effects of first generation BAB and can be widely used in the treatment of cardiovascular diseases, including hypertension. The results of numerous clinical studies confirming the high antihypertensive efficacy of bisoprolol and its favorable safety profile, including patients with carbohydrate metabolism disorders and broncho-obstructive pathology.

Авторлар туралы

V Makolkin

V Makolkin

Әдебиет тізімі

  1. The HDFP cooperative group. Persistence of reduction in blood pressure and mortality of participantesin the Hypertension Detection and Folloiw-up Program. JAMA 1988;259:2113-22.
  2. Guidelines for the Management of Arterial Hypertension. J Hypertension 2007;25:1105-87.
  3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр) // Кардиоваскулярная терапия и профилактика. 2008. № 6 Прил. 2.
  4. Gifford RW. To the Editor. JAMA 1988;260(12):1714-15.
  5. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise chouse? Lancet 2004;364:1684-89.
  6. Lindholm LH, Carlberg B, Samuelsson O. Shoud β-blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005;366:1545-53.
  7. Beevers DG. The end of β-blockers for uncomplicated hypertension? Lancet 2005;366:1510-12.
  8. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparison bisoprolol and nifedipine. J Am Coll Cardiol 1995;25:231-38.
  9. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the TIBBS. J Am Coll Cardiol 1996;28:20-24.
  10. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и соавт. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование АТР - Angina Treatment Pattern) // Кардиология. 2003. № 5. C. 9-15.
  11. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987;8:103-13.
  12. Buhtel FR, Berglund G, Anderson OK, et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986;4:144-46.
  13. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987;8(Suppl. M):65-69.
  14. Van der Ven LM, et al. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997;1:16-22.
  15. Mengden T, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997;8:55-67.
  16. Frishman W, Bryzinsci B, Coulson L, et al. A multifactorial trial design to assess combination therapy in hypertension. Arcn Intern Med 1994;154:1461-68.
  17. Goose P, Roudault R, Herrero G, et al. Beta-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990;16(Suppl. 5):145-50.
  18. Остроумова О.Д. Возможности применения высокоселективных β-адреноблокаторов у больных с сопутствующими заболеваниями // РМЖ. 2004. № 12. C. 721-725.
  19. CIBIS Investigators and Committees. A randomimixed trial of beta-blocade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
  20. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:913.
  21. Willenheimer R, van Vidhusen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol following by enаlaрril, as compared with the opposite sequence: results of the randomized Cardiac Insuffiency Bisoprolol Study (CIBIS) III. Circulation 2005;112(16):2426-35.
  22. Кукес В Г., Остроумова О.Д., Батурина А.М. и др. Бета-блокаторы в лечении артериальной гипертонии у больных с сахарным диабетом: противопоказание или препараты выбора? // РМЖ. 2002. № 10. С. 446-449.
  23. Остроумова О.Д., Батутина А.М. Выбор безопасного β-адреноблокатора у больных с сопутствующими хроническими обструктивными заболеваниями легких: преимущества бисопролола // РМЖ. 2003. № 9. С. 548-51.
  24. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2259&mid=1085056570&magid=169&full=1

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>